The $20mn round buys roughly 0.53 per cent of the company, and no product exists yet. Read the number as a reference price for pre-revenue bio-AI, not a verdict on the science.
Reality
- Evidence45
- Adoption3
- Hype gap+60
- Incentives65
- Confidence62
S32 led a $140M round that takes Basecamp Research's total funding to $225M since 2019. Two of the sixteen named backers, NVIDIA and Anthropic's Anthology Fund, are also partners on the dataset its models train on.
Perspective Coverage
3 publishers
- Builder
- Builder 30%
- Operator
- Operator 15%
- Investor
- Investor 55%
Reality
- Evidence55
- Adoption
- Not scored
- Hype gap+40
- Incentives75
- Confidence60
Obvious Ventures led $20M behind Mithrl's promise of a 50% faster path to IND
The Series A funds a second-generation platform. The only measured result the company has attached to it is a benchmark of its own showing 45% fewer tokens than uncustomized frontier models. Tokens are a compute cost.
Reality
- Evidence32
- Adoption24
- Hype gap+42
- Incentives78
- Confidence60
Massachusetts biotech: growth-stage money is back, seed money and NIH awards are not
MassBio's annual snapshot pairs a recovering VC, IPO and M&A market with a 39% fall in seed capital, a 6% drop in NIH awards and 3,605 lost jobs.
Reality
- Evidence61
- Adoption58
- Hype gap+12
- Incentives74
- Confidence63
buildConfirmed2 publishers The startup opened a robotic "human data center" near San Francisco on the thesis that AI drug discovery is limited by causal human experiments, not model capacity.
Reality
- Evidence44
- Adoption31
- Hype gap+24
- Incentives71
- Confidence56
Vivodyne says the AI drug bottleneck is human tissue data, not model capability
The startup opened what it calls the world's largest human data center last week. Its diagnosis of the field is testable; most of the evidence for its own machines is self-reported.
Reality
- Evidence34
- Adoption27
- Hype gap+32
- Incentives76
- Confidence44